Introduction {#sec1}
============

Cardiovascular diseases (CVD) are a leading cause of mortality in Western societies. In Poland, the network of approximately 160 interventional cardiology centers provides primary percutaneous coronary intervention (pPCI) service on a 24/7 basis with 735 pPCI/million inhabitants, thus providing low in-hospital mortality in the acute phase of myocardial infarction (MI). However, the post-discharge mortality in acute myocardial infarction (AMI) patients is high -- 10% after 1 year and almost 20% after 3 years \[[@cit0001]\]. European Society of Cardiology (ESC) registries show that the 1-year mortality rate reached 4--12% and is highly variable across Europe. This is similar to data reported from the USA and European countries \[[@cit0002]--[@cit0004]\]. The studies suggest that efforts should focus on post-MI care and secondary prevention of CVD \[[@cit0005]--[@cit0007]\].

The analysis of the post-discharge period shows a particularly high risk of complications within the first several months after MI. The causes comprise insufficient control of risk factors, poor adherence to medication, and the lack of balanced physical activity, which derives mostly from low access to cardiac rehabilitation (CR) programs, as well as poor access to outpatient cardiology care \[[@cit0008]--[@cit0010]\]. Managed Care in Acute Myocardial Infarction (MC-AMI, KOS-zawał) is a program introduced by Poland's National Health Fund and Ministry of Health aiming at comprehensive care for patients with AMI to improve post-discharge prognosis. It includes acute intervention, complex revascularization, CR, scheduled outpatient follow-up, and prevention of SCD in eligible subjects \[[@cit0011], [@cit0012]\].

The aim of the analysis was to assess the relation between participation in MC-AMI and major adverse cardiovascular events (MACE, a composite of death, recurrent myocardial infarction, and hospitalization for heart failure (HF)) in 3-month follow-up. Additionally we assessed the relation between MC-AMI and other clinical variables and MACE in the studied group.

Material and methods {#sec2}
====================

We present a retrospective analysis from a single, high-volume tertiary cardiology care center.

Study and control group. Principles of MC-AMI {#sec2.1}
---------------------------------------------

The study group consisted of all consecutive subjects diagnosed with AMI from 1 Nov 2017 to 31 Aug 2018 who consented to participation in MC-AMI. All patients with AMI, aged \> 18 years old who gave informed consent for participation in MC-AMI were included in the unmatched study group. Patients were followed up to 30 Nov 2018. The participation in MC-AMI ensured diagnostics and interventional therapy in AMI according to ESC guidelines (Module I), cardiac rehabilitation (outpatient or in-hospital) (Module II), implantation of ICD or CRT-D in eligible subjects (Module III), and 12-month scheduled, outpatient cardiology care and follow-up (Module IV). The study flowchart is presented in [Figure 1](#f0001){ref-type="fig"}. In this analysis only the first 3 months were taken into account. During this period, patients participated in module I, module II, and partially module IV (in most cases visit 1 only). After AMI-related hospitalization, patients who consented to participation in MC-AMI had a screening visit scheduled for 7--10 days after discharge. The screening visit covered clinical assessment by a cardiologist, ECG and basic blood tests (full blood count, CrCl, CRP). Unless contraindicated, patients were then qualified for cardiac rehabilitation (described below), which started not later than 14 days after discharge. Upon CR completion, patients attended visit 1 that was scheduled 6 weeks after discharge from hospital (MI-related hospitalization). During visit 1, clinical assessment and echocardiography was performed to search for patients eligible for implantation of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT). Additionally, the course of MC-AMI schedule in a particular patient depended on several factors, the most important being staged revascularization (PCI/CABG; in these cases rehabilitation was scheduled after full revascularization) and potential indication for ICD/CRT-D. The 3-month analysis we perform covers module I, II, and the first part of ambulatory follow-up.

![MC-AMI (KOS-zawał) flowchart](AMS-16-3-36848-g001){#f0001}

The control group consisted of AMI patients who were hospitalized in our center within 1 year prior to the introduction of the MC-AMI program. Data from all consecutive admissions with AMI diagnosis between 1 Nov 2016 and 31 Aug 2017 were used for analysis. These patients were followed up to 30 Nov 2017.

For initial analysis, we recruited an overall number of 2341 patients with AMI (1211 (51.7%) patients were enrolled in the study group and 1130 (48.3%) in the control group). In the study group, there were 69 (5.7%) in-hospital deaths. Out of the remaining 1142 subjects, 719 (63%) consented to participation in MC-AMI. In the control group there were 67 (5.9%) in-hospital deaths and the remaining 1063 patients were analyzed as an unmatched control group.

To reduce selection bias we performed 1 : 1 propensity score matching (PSM) between the study and the control group using pre-specified clinical variables, including age, sex, hypertension, diabetes mellitus, dyslipidemia, smoking, chronic kidney disease, stroke, presentation as ST-elevation myocardial infarction (STEMI), presence of multivessel disease and left ventricular ejection fraction (LVEF).

AMI-related hospitalization {#sec2.2}
---------------------------

Myocardial infarction was diagnosed in line with the Third Universal Definition of Myocardial Infarction. Coronary angiography was performed via either the radial or femoral artery by a standard technique. The stent type used was at the individual operator's discretion. Standard post-MI pharmacotherapy was used according to the European Society of Cardiology recommendations unless contraindicated. Medication is summarized in [Table I](#t0001){ref-type="table"}. Transthoracic echocardiography was performed to assess the left ventricular ejection fraction (LVEF) using the modified Simpson's biplanar method. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate \< 60 ml/min/1.73 m^2^.

###### 

Baseline characteristics in unmatched study groups (*n* = 1782)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                  Unmatched study group *N* = 719\          Unmatched control group *N* = 1063\       *P*-value                                                
                             Mean ± SD or median (1Q--3Q) or *n* (%)   Mean ± SD or median (1Q--3Q) or *n* (%)                                                            
  -------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------ ------------- ---------------------------------------------
  Age \[years\]              65.97 ±10.55                              66 (59--77)                               68.61 ±11.27                               68 (60--76)   \< 0.0001^[I](#tf1-1){ref-type="table-fn"}^

  LVEF (%)                   45.74 ±10.64                              48 (39--55)                               44.01 ±11.57                               48 (36--55)   0.001^[I](#tf1-1){ref-type="table-fn"}^

  Female sex                 220 (30.6)                                361 (33.9)                                0.146^[II](#tf1-2){ref-type="table-fn"}^                 

  History of CHD             351 (48.9)                                519 (48.9)                                0.995^[II](#tf1-2){ref-type="table-fn"}^                 

  Arterial hypertension      564 (78.6)                                881(82.8)                                 0.030^[II](#tf1-2){ref-type="table-fn"}^                 

  Diabetes mellitus          227 (31.6)                                338 (31.8)                                0.925^[II](#tf1-2){ref-type="table-fn"}^                 

  Hyperlipidemia             490 (68.2)                                792 (74.4)                                0.001^[II](#tf1-2){ref-type="table-fn"}^                 

  Previous stroke            41 (5.7)                                  96 (9.0)                                  0.010^[II](#tf1-2){ref-type="table-fn"}^                 

  CKD                        120 (16.7)                                26.6 (26.6)                               0.001^[II](#tf1-2){ref-type="table-fn"}^                 

  Smoking                    293 (40.8)                                479 (451)                                 0.087^[II](#tf1-2){ref-type="table-fn"}^                 

  Previous STEMI             97 (13.5)                                 165 (5.5)                                 0.246^[II](#tf1-2){ref-type="table-fn"}^                 

  Previous NSTEMI            116 (16.2)                                179 (16.8)                                0.707^[II](#tf1-2){ref-type="table-fn"}^                 

  Previous PCI               219 (30.5)                                310 (29.1)                                0.555^[II](#tf1-2){ref-type="table-fn"}^                 

  Previous CABG              80 (11.1)                                 148 (13.9)                                0.084^[II](#tf1-2){ref-type="table-fn"}^                 

  NSTEMI presentation        482 (67.1)                                733 (68.8)                                0.401^[II](#tf1-2){ref-type="table-fn"}^                 

  STEMI presentation         236 (32.9)                                331 (30.2)                                0.337^[II](#tf1-2){ref-type="table-fn"}^                 

  Multivessel disease        433 (60.3)                                746 (70.1)                                0.001^[II](#tf1-2){ref-type="table-fn"}^                 

  Medication at discharge:                                                                                                                                                

   ASA                       719 (100)                                 1063 (100)                                --                                                       

   P2Y12 inhibitor           704 (97.9)                                1030 (96.9)                               0.19^[II](#tf1-2){ref-type="table-fn"}^                  

   β-Blockers                632 (87.9)                                920 (86.5)                                0.40^[II](#tf1-2){ref-type="table-fn"}^                  

   ACE-I                     654 (91.0)                                940 (88.4)                                0.09^[II](#tf1-2){ref-type="table-fn"}^                  

   Statins                   701 (97.5)                                1020 (96)                                 0.08^[II](#tf1-2){ref-type="table-fn"}^                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mann-Whitney U test,

Pearson χ^2^ test. CAD -- coronary artery disease, MI -- myocardial infarction, PCI -- percutaneous coronary intervention, CABG -- coronary artery bypass grafting, CHD -- coronary heart disease, CKD -- chronic kidney disease, STEMI -- ST-elevation myocardial infarction, NSTEMI -- non-ST-elevation myocardial infarction, LVEF -- left ventricular ejection fraction, SD -- standard deviation, ACE-I -- angiotensin converting enzyme inhibitors, ASA -- acetylsalicylic acid.

Cardiac rehabilitation {#sec2.3}
----------------------

Cardiac rehabilitation was preceded by a screening visit (7--10 days after discharge) and performed in an outpatient cardiac rehabilitation facility (22 days) or in-hospital cardiac rehabilitation ward (hospitalization up to 35 consecutive days). The key criterion for in-hospital rehabilitation was EF ≤ 35% Additionally, patients with serious comorbidities and frailty could be qualified for in-hospital CR regardless of EF.

Follow-up ECG, transthoracic echocardiography (TTE), 6-minute walk test (6MWT) and treadmill test were performed in all patients during cardiac rehabilitation. The CR program included all core components recommended by the European Society of Cardiology. At baseline an exercise treadmill test (ETT) was performed to tailor the CR program to the patient's exercise capacity. The rehabilitation program included interval training on an ergometer, group and individualized, supervised physical training, as well as a psychological program, including group therapy and relaxation sessions. Moreover, educational sessions on lifestyle modification and coronary risk factors control were included in the program.

Endpoints {#sec2.4}
---------

Follow-up data, including exact dates of deaths, MI, and repeat hospitalization for HF, were obtained from the health insurer (National Health Fund). The MACE were defined as a composite of all-cause mortality, recurrent myocardial infarction, and hospitalization for HF. Hospitalization for HF was defined as admission to a health care facility lasting \> 24 h due to worsening of symptoms of HF and followed by specific HF treatment (regardless of the cause of decompensation).

Ethics {#sec2.5}
------

The study protocol was approved by the Ethics Committee of the Medical University of Silesia in Katowice.

Statistical analysis {#sec2.6}
--------------------

Statistical analysis was performed with SPSS v.25.0 software (IBM Corp, Armonk, NY, USA). First, 1 : 1 propensity score matching using the nearest neighbor method was implemented in order to compensate for the imbalance in terms of baseline covariates between MC-AMI and the control group. The overall Hansen and Bowers balance test showed good case alignment (*p* = 0.998). Out of the initial 1782 patients, a cohort of 1058 patients was incorporated into the final analysis.

Quantitative variables were specified as mean and standard deviation (SD) or median and 25--75 percentile boundaries, whereas qualitative parameters were expressed as number and percentage. Variable's type of distribution was verified using the Shapiro-Wilk test. Since all continuous variables were non-normally distributed, the two-tailed Mann-Whitney *U* test was used to compare inter-group differences. Qualitative parameters were compared using Pearson's χ^2^ test. Relative risk (RR) ratios with 95% confidence intervals (95% CI) were calculated. All the variables with *p* \< 0.1 in the univariate model were included in the Cox proportional hazards model using backward stepwise Wald's approach. The Kaplan-Meier survival curves for the MC-AMI (group A) and control group (group B) were established and log-rank tests were calculated. A *p*-value of less than 0.05 was regarded as statistically significant.

Results {#sec3}
=======

Baseline characteristics of unmatched study groups are presented in [Table I](#t0001){ref-type="table"}. After PSM, we selected a group of 1058 well-balanced pairs (529 in MC-AMI group and 529 in control) with a good bias reduction in most of the parameters ([Table II](#t0002){ref-type="table"}). The incidence of congestive heart failure at baseline was similar in study and control cohorts (44.6% vs. 46.5%; *p* = 0.537).

###### 

Baseline characteristics of two study groups after propensity score matching

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                   Total *N* = 1058\                         Matched study group *N* = 529\            Matched control group *N* = 529\          *P*-value
                              Mean ± SD or median (1Q--3Q) or *n* (%)   Mean ± SD or median (1Q--3Q) or *n* (%)   Mean ± SD or median (1Q--3Q) or *n* (%)   
  --------------------------- ----------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------
  Age \[years\]               66.37 ±10.94 66 (59--75)                  66.36 ±10.53 66 (59--74)                  66.40 ±11.34 67 (59--75)                  0.846^[I](#tf2-1){ref-type="table-fn"}^

  LVEF (%)                    45.54 ±10.89 48 (40--55)                  45.76 ±10.84 48 (40--55)                  45.33 ±10.95 48 (38--55)                  0.574^[I](#tf2-1){ref-type="table-fn"}^

  eGFR \[ml/min/1.73 m^2^\]   73.17 ±19.41 79 (63--90)                  73.87 ±18.14 79 (63--90)                  72.46 ±20.61 78 (62--90)                  0.815^[I](#tf2-1){ref-type="table-fn"}^

  Female sex                  341 (32.2)                                167 (31.6)                                174 (32.9)                                0.645^[II](#tf2-2){ref-type="table-fn"}^

  CHD                         548 (51.8)                                270 (51.0)                                278 (52.6)                                0.623^[II](#tf2-2){ref-type="table-fn"}^

  Arterial hypertension       852 (80.5)                                424 (80.2)                                428 (80.9)                                0.756^[II](#tf2-2){ref-type="table-fn"}^

  Diabetes mellitus           339 (32.0)                                168 (31.8)                                171 (32.3)                                0.843^[II](#tf2-2){ref-type="table-fn"}^

  Hyperlipidemia              778 (73.5)                                391 (73.9)                                387 (73.2)                                0.780^[II](#tf2-2){ref-type="table-fn"}^

  Previous stroke             58 (5.5)                                  26 (4.9)                                  32 (6.0)                                  0.418^[II](#tf2-2){ref-type="table-fn"}^

  CKD                         188 (17.8)                                92 (17.4)                                 96 (18.1)                                 0.748^[II](#tf2-2){ref-type="table-fn"}^

  Smoking                     443 (41.9)                                215 (40.6)                                228 (43.1)                                0.418^[II](#tf2-2){ref-type="table-fn"}^

  Previous STEMI              166 (15.7)                                81 (15.3)                                 85 (16.1)                                 0.735^[II](#tf2-2){ref-type="table-fn"}^

  Previous NSTEMI             197 (18.6)                                93 (17.6)                                 104 (19.7)                                0.385^[II](#tf2-2){ref-type="table-fn"}^

  Previous PCI                345 (32.6)                                168 (31.8)                                177 (33.5)                                0.555^[II](#tf2-2){ref-type="table-fn"}^

  Previous CABG               129 (12.2)                                63 (11.9)                                 66 (12.5)                                 0.778^[II](#tf2-2){ref-type="table-fn"}^

  NSTEMI presentation         716 (67.7)                                352 (66.5)                                364 (68.8)                                0.430^[II](#tf2-2){ref-type="table-fn"}^

  STEMI presentation          330 (31.2)                                170 (32.1)                                160 (30.2)                                0.507^[II](#tf2-2){ref-type="table-fn"}^

  Multivessel disease         604 (57.1)                                294 (55.6)                                310 (58.6)                                0.320^[II](#tf2-2){ref-type="table-fn"}^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mann-Whitney U test;

Pearson χ^2^ test. CAD -- coronary artery disease, MI -- myocardial infarction, PCI -- percutaneous coronary intervention, CABG -- coronary artery bypass grafting, CHD -- coronary heart disease, CKD -- chronic, kidney disease, STEMI -- ST-elevation myocardial infarction, NSTEMI -- non-ST-elevation myocardial infarction, LVEF -- left ventricular ejection fraction, SD -- standard deviation.

In a 3-month follow-up the occurrence of the MACE composite endpoint was almost twice as common in the control as in the study group (4.9% vs. 8.9%, *p* = 0.012), as shown in [Table III](#t0003){ref-type="table"} and in Kaplan-Meier curves ([Figure 2](#f0002){ref-type="fig"}). Death, recurrent MI and hospitalization for HF were more common in the control group, but the difference was not statistically significant ([Table III](#t0003){ref-type="table"}).

![Kaplan-Meier survival curves -- MACE in 3-month observation](AMS-16-3-36848-g002){#f0002}

###### 

Comparison of study endpoints between MC-AMI group and control group in 3-month observation (propensity score matching)

  Parameter                Total *N* = 1058 *n* (%)   MC-AMI group *N* = 529 *n* (%)   Control group *N* = 529 *n* (%)   RR      95% CI         NNT     *P*-value[\*](#tf3-1){ref-type="table-fn"}
  ------------------------ -------------------------- -------------------------------- --------------------------------- ------- -------------- ------- --------------------------------------------
  All-cause mortality      19 (1.8)                   7 (1.3)                          12 (2.3)                          0.583   0.232--1.470   105.8   0.247
  Hospitalization for HF   31 (2.9)                   12 (2.3)                         19 (3.6)                          0.632   0.310--1.288   75.6    0.202
  Myocardial infarction    25 (2.4)                   9 (1.7)                          16 (3.0)                          0.563   0.251--1.262   75.6    0.157
  MACE                     73 (6.9)                   26 (4.9)^\#^                     47 (8.9)                          0.553   0.348--0.879   25.2    0.012

Two-tailed Pearson's χ^2^ test; MACE -- major adverse cardiovascular events.

Number of patients with at least one MACE; in 2 patients 2 endpoints occurred. This explains why the total number of MACE is lower than the sum of all endpoints.

Multivariable Cox regression analysis revealed MC-AMI participation to be inversely associated with the occurrence of MACE at 3 months (HR = 0.476, 95% CI: 0.283--0.799, *p* \< 0.005). Also, older age (1.037/year; 95% CI: 1.007--1.056), male sex (HR = 0.54; 95% CI: 0.31-0.95 for female), history of unstable angina (HR = 3.15; 95% CI: 1.68--5.91), peripheral artery disease (HR = 2.17, 95% CI: 1.24--3.79), peri-MI atrial fibrillation (HR = 1.87, 95% CI: 1.06--3.23) and diabetes (HR = 1.58, 95% CI: 0.97--2.52) were associated with the primary endpoint.

Almost all patients in the matched study group (520 out of 529; 98.3%) were enrolled in an early cardiac rehabilitation (ECR) program; 56.1% (297 out of 529 patients) were qualified for in-hospital rehabilitation, while 42.2% (223 out of 529 patients) attended an outpatient CR program. In the control group, only 75 out of 529 subjects (14.2%) participated in CR (in-hospital CR, 63 patients; outpatient CR, 12 patients), which was significantly fewer than in the MC-AMI group (*p* \< 0.001)

Discussion {#sec4}
==========

Despite good results of medical and interventional treatment of AMI and low in-hospital mortality, there is an emerging need for comprehensive post-discharge medical care to reduce long-term adverse events and to improve patients' exercise capacity and quality of life.

MC-AMI is the first nation-wide, structured, comprehensive and supervised care system, close to the optimal and guideline-recommended management, which is hardly met in real-world conditions. We hereby present data showing the benefit of MC-AMI participants with regard to reduction of hard clinical endpoints. Primarily, we have found a 45% relative risk reduction of MACE in 3-month observation. To the best of our knowledge, this is the first study to address the relation between complex care strategy and hard clinical endpoints in post-AMI patients.

In our cohort, in-hospital mortality, medical therapy and interventional treatment were similar in both groups. One limitation of the study is that the cohorts compared are non-contemporaneous. However, neither treatment guidelines nor local polices had changed over the period when the analysis was performed. The alternative approach for retrospective analysis would be to compare the data of MC-AMI participants to those who did not consent to MC-AMI. From our experience, however, the patients who refused to consent were quite a different (and heterogeneous) group, compared to those who consented to participation, and compared to a general population of MI survivors. While almost all patients qualified for in-hospital CR agreed to participate, patients qualified for outpatient CR presented with more obstacles (difficulty with everyday traveling to the CR facility, distance from home to CR etc.). Furthermore, despite intensive education, patients with milder symptoms and in-hospital course of the MI were more difficult to convince and to show them benefits coming from CR. Another group of patients who did not agree were the elderly and fragile patients who were either unable or unwilling to participate. Finally, comparing MC-AMI patients to a similar cohort from one year before allowed for a reasonably powered analysis, which would not have been possible if we had chosen the non-consenting cohort (*n* = 423 over the analyzed period). Thus, we decided to match our study group to a cohort from a similar period, but 1 year before.

As stated, the patients in the MC-AMI and control group were matched to compensate the imbalance in risk factors and major MI-related clinical data. Thus, the MACE reduction is attributable to the management in the post-discharge period.

According to the current guidelines, post-MI patients should participate in a cardiac rehabilitation program \[[@cit0013]\]. In a large meta-analysis, Anderson *et al.* \[[@cit0014]\] revealed that CR reduces cardiovascular mortality by 22%, but does not affect all-cause mortality. In our study, where participation in CR was one of the crucial factors differentiating study and control groups, we also did not observe long-term all-cause mortality reduction, but participation in MC-AMI reduced MACE by 45% as soon as in 3 months.

In the most complex meta-analysis by Kabboul *et al.* \[[@cit0015]\] (148 studies, 50965 patients), in which not only exercise capacity but also nutritional counseling, risk factor modification, psychosocial management, and patient education were analyzed, the authors found that different components of a complex CR program have a different effect on adverse events reduction. Not only physical training but also psychosocial management and patient education were found to influence the endpoints. In our study, the above-mentioned components were included in the program, and are presumed to have participated in MACE reduction by improving compliance.

In a multivariable Cox regression model participation in MC AMI was one of the strongest negative predictors of MACE (HR = 0.48, *p* \< 0.001). As MC-AMI is the first comprehensive post-discharge management program for AMI patients, there are no data to compare our results to in the literature. We can, however, compare them to studies assessing effects of the components of MC-AMI, particularly CR.

In the CROS meta-analysis, mortality reduction for post-ACS CR participants was 0.49--0.84 in retrospective studies and 0.20--0.69 for prospective ones \[[@cit0016]\]. In a large Dutch cohort, CR significantly improved 4-year survival with an HR of 0.65 (95% CI: 0.56--0.77), with the largest benefit observed for patients who underwent CABG and/or valve surgery (HR = 0.55, 95% CI: 0.42--0.74) \[[@cit0017]\]. In our study, the benefit from MC-AMI was measured primarily in MACE reduction and, although it is not possible to compare it directly, seems higher than in most retrospective studies in the CROS meta-analysis.

In our opinion it is the complex approach in MC-AMI that warrants better adverse events reduction over a shorter time. It seems, however, that in a 3-month observation the most important factors are cardiac rehabilitation and close, supervised follow-up. Importantly, such an approach has a good perception among participants, as recently reported by Feusette *et al.* \[[@cit0018]\].

In our analysis, besides MC-AMI participation, older age, male sex, history of unstable angina, peripheral artery disease, peri-MI atrial fibrillation, and diabetes were found to be related to the risk of MACE. The observations are consistent with the literature; there is however a large variety of factors taken into the analysis in different studies.

The observation is a retrospective cohort study, so only a statistical association rather than causal relationships could be confirmed. Moreover, the analysis was performed in a single center cohort. A multicenter analysis would provide more insight into local differences in implementation of the MC-AMI program in everyday practice. Finally, despite very encouraging results of 3-month observation, a longer follow-up will be necessary to prove a long-term benefit of the program.

In conclusion, participation in MC-AMI -- the first comprehensive in-hospital and post-discharge care for AMI patients -- improves prognosis and reduces the MACE rate by 45% as soon as in 3-month follow-up.
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